Hovione

Activity by year

2017201820192020202120222023202420252026

AcquisitionContract

Sep 28, 2020CONTRACT
Hovione to ramp up output of Ligand's Captisol for COVID-19 treatment
Hovione has signed an agreement to significantly increase production of Ligand Pharmaceuticals' Captisol excipient, used in Gilead's remdesivir COVID-19 treatment, with monthly output soon matching previous annual production.
Hovione supplier Ligand Pharmaceuticals customer Gilead Sciences partner #Specialty Chemicals doi.org
Apr 1, 2017ACQUISITION
H&T Presspart acquires global rights to Hovione's dry powder inhaler
H&T Presspart announced the acquisition of global rights to a capsule-based dry powder inhaler developed by Hovione, which will be manufactured and commercialized as PowdAir Plus. The companies will continue to collaborate.
H&T Presspart acquirer Hovione target #Medical Devices oindpnews.com

Customers

Acquired by

Loading…